Nationwide status of progestogen treatment to prevent spontaneous preterm birth: A questionnaire survey for childbirth healthcare facilities in Japan.
Ikuno KawabataTakeshi NagamatsuSatoshi YonedaRie OiYoshio MatsudaAkihito NakaiKatsufumi OtsukiPublished in: The journal of obstetrics and gynaecology research (2024)
Due to the current regulations of the Japanese health insurance system, 17α-hydroxyprogesterone caproate, rather than vaginal progesterone, was mainly used for PTB prevention. Despite global evidence supporting vaginal progesterone as the approach with the highest efficacy, only a limited number of facilities have utilized it due to the current drug use regulations in Japan.